Stay informed on the latest Truth Social posts from Donald Trump (@realDonaldTrump) without the doomscrolling. Consider it a public service for your mental health. (Why?)
Filtering by entity: Medicaid | Clear Filter
Summary:The White House, under Donald Trump, has issued a directive to AstraZeneca and all drug manufacturers to implement Most-Favored-Nation (MFN) drug pricing for American patients, aiming to stop other nations from "freeloading" on American innovation and to lower prescription drug costs significantly by September 29, 2025.
Sentiment:Directive/Demanding
Key Claims:
- Americans currently pay up to three times more for identical prescription drugs than patients in other developed nations.
- Other nations are "freeloading" on American innovation in drug development.
- An Executive Order on "Most-Favored-Nation Prescription Drug Pricing" was signed on May 12, 2025.
- Drug manufacturers are called upon to extend MFN pricing to Medicaid, guarantee MFN pricing for newly-launched drugs, return increased revenues from abroad to American patients, and offer direct purchasing at MFN prices.
- The Administration is prepared to use every tool to protect Americans from abusive drug pricing practices if cooperation is not met.
- Binding commitments for these goals are expected by September 29, 2025.
Potential Market Impact (S&P 500):8/10
Potential Geopolitical Risk:0/10
Potential Global Cross-Asset Impact:7/10
Summary:A letter from the White House dated July 31, 2025, sent to Amgen, demands that drug manufacturers implement actions within 60 days, by September 29, 2025, to lower prescription drug prices for American patients to Most-Favored-Nation rates. The letter asserts that the US currently pays significantly more for brand name drugs than other developed nations due to 'global freeloading' and highlights an Executive Order signed on May 12, 2025, aimed at addressing this disparity.
Sentiment:Directive
Key Claims:
- An Executive Order titled 'Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients' was signed on May 12, 2025.
- Brand name drug prices in the United States are up to three times higher than elsewhere, attributed to 'global freeloading' and an 'unacceptable burden' on American families.
- Amgen and all manufacturers are called upon to implement specific actions within 60 days to address inflated drug prices.
- Required actions include extending Most-Favored-Nation (MFN) pricing to Medicaid, guaranteeing MFN pricing for newly-launched drugs, returning increased revenues from abroad to American patients and taxpayers, and providing for direct purchasing at MFN pricing.
- The administration is prepared to deploy 'every tool in our arsenal' to protect American families from 'abusive drug pricing practices' if manufacturers do not comply.
- The deadline for achieving these goals is September 29, 2025.
Potential Market Impact (S&P 500):8/10
Potential Geopolitical Risk:2/10
Potential Global Cross-Asset Impact:7/10